Base de dados : MEDLINE
Pesquisa : D12.776.124.486.485.114.254.450.251 [Categoria DeCS]
Referências encontradas : 1151 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 116 ir para página                         

  1 / 1151 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29036227
[Au] Autor:Lee YL; Lin KY; Cheng CY; Li CW; Yang CJ; Tsai MS; Tang HJ; Lin TY; Wang NC; Lee YC; Lin SP; Huang YS; Sun HY; Zhang JY; Ko WC; Cheng SH; Lee YT; Liu CE; Hung CC; Taiwan HIV Study Group
[Ad] Endereço:Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan.
[Ti] Título:Evolution of hepatitis A virus seroprevalence among HIV-positive adults in Taiwan.
[So] Source:PLoS One;12(10):e0186338, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: The study aimed to describe the seroprevalence of hepatitis A virus (HAV) in HIV-positive adult patients in Taiwan between 2012 and 2016 and to examine the evolution of HAV seroprevalence between 2004-2007 and 2012-2016. METHODS: Clinical information and data of anti-HAV antibody results were collected from 2,860 antiretroviral-naïve HIV-positive Taiwanese aged 18 years or older who initiated combination antiretroviral therapy at 11 hospitals around Taiwan between 2012 and 2016 (2012-2016 cohort). A multivariate logistic regression model was applied to identify independent variables associated with HAV seropositivity. Comparisons of HAV seroprevalences and associated clinical characteristics were made between this 2012-2016 cohort and a previous cohort of 1580 HIV-positive patients in 2004-2007 (2004-2007 cohort). RESULTS: Of the 2,860 HIV-positive patients between 2012 and 2016, the overall HAV seropositivity rate was 21.2% (605/2860), which was independently associated with an older age (adjusted odds ratio [AOR], per 1-year increase, 1.13; 95% confidence interval [95% CI], 1.11-1.15) and co-infection with hepatitis B virus (AOR 1.44; 95% CI, 1.08-1.93). Residence in southern Taiwan (AOR 0.49; 95% CI, 0.34-0.72) was inversely associated with HAV seropositivity. The overall HAV seroprevalence in the 2012-2016 cohort was significantly lower than that in the 2004-2007 cohort (21.2% vs 60.9%, p<0.01). The decreases of HAV seropositivity rate were observed in nearly every age-matched group, which suggested the cohort effect on HAV seroepidemiology. However, among individuals aged 25 years or younger, the HAV seropositivity rate increased from 3.8% (2/52) in the 2004-2007 cohort to 8.5% (50/587) in the 2012-2016 cohort, with 95.4% (560/587) being MSM in this age group of the latter cohort. CONCLUSIONS: HAV seroprevalence has decreased with time among HIV-positive adults in Taiwan. The cohort effect has increased the number of young HIV-positive patients that are susceptible to HAV infection in a country without nationwide childhood vaccination program against HAV.
[Mh] Termos MeSH primário: Infecções por HIV/sangue
Infecções por HIV/imunologia
Anticorpos Anti-Hepatite A/sangue
Vírus da Hepatite A/imunologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Fatores Etários
Fármacos Anti-HIV/uso terapêutico
Feminino
Infecções por HIV/tratamento farmacológico
Infecções por HIV/epidemiologia
Hepatite A/prevenção & controle
Vacinas contra Hepatite A/administração & dosagem
Seres Humanos
Modelos Logísticos
Masculino
Meia-Idade
Análise Multivariada
Estudos Retrospectivos
Estudos Soroepidemiológicos
Taiwan/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-HIV Agents); 0 (Hepatitis A Antibodies); 0 (Hepatitis A Vaccines)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171017
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0186338


  2 / 1151 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28800730
[Au] Autor:Yilmaz H; Karakullukcu A; Turan N; Cizmecigil UY; Yilmaz A; Ozkul AA; Aydin O; Gunduz A; Mete M; Zeyrek FY; Kirazoglu TT; Richt JA; Kocazeybek B
[Ad] Endereço:Department of Virology, Veterinary Faculty, University of Istanbul, Avcilar, Istanbul, Turkey. hyilmaz@istanbul.edu.tr.
[Ti] Título:Genotypes of hepatitis a virus in Turkey: first report and clinical profile of children infected with sub-genotypes IA and IIIA.
[So] Source:BMC Infect Dis;17(1):561, 2017 Aug 11.
[Is] ISSN:1471-2334
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Hepatitis A virus (HAV) is a food and water-borne virus causing clinical (mainly hepatitis) and subclinical disease in humans. It is important to characterize circulating strains of HAV in order to prevent HAV infections using efficacious vaccines. The aim of this study was the detection and characterization of the circulating strains of HAV in Turkey by performing serology, RT-PCR, sequencing and phylogenetic analysis. METHODS: In this study, 355 HAV suspected cases were analysed by ELISA for the presence of antibodies to HAV. RNA was extracted from 54 HAV IgM positive human sera. None of the suspect cases were vaccinated against HAV and they never received blood transfusions. Samples found positive by RT-PCR using primers targeting the VP1/VP2A junction and VP1/VP3 capsid region of HAV, were subjected to sequencing and phylogenetic analyses. RESULTS: IgM type antibodies to HAV were detected in 54 patients. Twenty one of them were students. The age of IgM positive cases was between 3 and 60 years. IgM positivity differed in age groups and was higher in the age group 3 to 10 years. Phylogenetic analysis showed that the majority of HAV strains detected in this study belong to the "HAV 1B" cluster. In addition, the HAV sub-genotypes IA (KT874461.1) and IIIA (KT222963.1) were found in 2 children. These sub-genotypes were not previously reported in Turkey. The child who carried sub-genotype IIIA travelled to Afghanistan and presented with abdominal pain, icterus and vomitus. He was positive for anti-HAV IgM and IgG but negative for hepatitis B and C. Liver enzymes like aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transferase and lactate dehydrogenase were severely elevated. Bilirubin levels were also increased. White blood cells, neutrophils and hemoglobin were decreased while lymphocytes and monocytes were increased. Similar clinical signs and laboratory findings were reported for the child infected with sub-genotype IA but aspartate aminotransferase and alanine aminotransferase were not severely elevated. CONCLUSIONS: The results indicate that molecular studies determining the HAV genotype variation in Turkey are timely and warranted. The majority of IgM positive cases in 3-10 year old patients indicate that childhood vaccination is important. Sub-genotype IB is the most prevalant genotype in Turkey. Surprisingly, sub-genotype IA and IIIA are also present in Turkey; future diagnostic efforts need to include diagnostic methods which can identify this emerging HAV genotypes. Our results also show that one important risk factor for contracting hepatitis A virus is international travel since genotype IIIA was detected in a child who had travelled to Afghanistan.
[Mh] Termos MeSH primário: Vírus da Hepatite A/genética
Hepatite A/etiologia
Filogenia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Afeganistão
Criança
Pré-Escolar
Feminino
Genótipo
Hepatite A/virologia
Anticorpos Anti-Hepatite A/sangue
Vírus da Hepatite A/isolamento & purificação
Vírus da Hepatite A/patogenicidade
Seres Humanos
Fígado/enzimologia
Fígado/virologia
Masculino
Meia-Idade
Turquia
Proteínas Estruturais Virais/genética
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hepatitis A Antibodies); 0 (VP1 protein, hepatitis A virus); 0 (Viral Structural Proteins)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170813
[St] Status:MEDLINE
[do] DOI:10.1186/s12879-017-2667-3


  3 / 1151 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28721859
[Au] Autor:Maritsi DN; Coffin SE; Argyri I; Vartzelis G; Spyridis N; Tsolia MN
[Ad] Endereço:Second Department of Paediatrics, P. & A. Kyriakou Children's Hospital, University of Athens, Greece. dmaritsi@gmail.com.
[Ti] Título:Immunogenicity and safety of the inactivated hepatitis A vaccine in children with juvenile idiopathic arthritis on methotrexate treatment: a matched case-control study.
[So] Source:Clin Exp Rheumatol;35(4):711-715, 2017 Jul-Aug.
[Is] ISSN:0392-856X
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To describe the immunogenicity and side effects of immunisation against hepatitis A virus (HAV) in JIA patients on methotrexate treatment, who have not been previously exposed to HAV. METHODS: Case-control study performed in JIA patients and healthy controls matched on age and gender. The subjects received two doses of inactivated anti-HAV vaccine (720 mIU/ml) intramuscularly at 0 and 6 months. Seroconversion, seroprotection rates and anti-HAV-IgG titres were measured at 1, 7 and 18 months. Children were monitored for adverse events. RESULTS: 83 JIA patients and 76 controls were enrolled in the study. At one month, seroprotection rates were lower in children with, as compared to those without JIA (48.2% vs. 65%; p=0.05). At 7 and 18 months, rates of seroprotection rose significantly and were similar in both groups. The titre of anti-HAV-IgG was lower in children with JIA than healthy children at all time points (p<0.001). Vaccines were well tolerated. CONCLUSIONS: Two doses of inactivated HAV vaccine were well tolerated and immunogenic in most immunosuppressed children with JIA; however, a single dose of HAV vaccine was insufficient to induce seroprotection in half of the patients. Further studies are required to analyse the long-term immunity against HAV in this population and optimal HAV immunisation regimen.
[Mh] Termos MeSH primário: Artrite Juvenil/tratamento farmacológico
Anticorpos Anti-Hepatite A/imunologia
Vacinas contra Hepatite A/uso terapêutico
Hepatite A/prevenção & controle
Imunogenicidade da Vacina/imunologia
Imunoglobulina G/imunologia
Imunossupressores/uso terapêutico
Metotrexato/uso terapêutico
[Mh] Termos MeSH secundário: Artrite Juvenil/imunologia
Estudos de Casos e Controles
Criança
Pré-Escolar
Feminino
Vacinas contra Hepatite A/imunologia
Seres Humanos
Masculino
Vacinas de Produtos Inativados/imunologia
Vacinas de Produtos Inativados/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hepatitis A Antibodies); 0 (Hepatitis A Vaccines); 0 (Immunoglobulin G); 0 (Immunosuppressive Agents); 0 (Vaccines, Inactivated); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170831
[Lr] Data última revisão:
170831
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170720
[St] Status:MEDLINE


  4 / 1151 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28705178
[Au] Autor:Bruni R; Taffon S; Equestre M; Cella E; Lo Presti A; Costantino A; Chionne P; Madonna E; Golkocheva-Markova E; Bankova D; Ciccozzi M; Teoharov P; Ciccaglione AR
[Ad] Endereço:National Reference Laboratory for HAV, Viral Hepatitis Unit, Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy. roberto.bruni@iss.it.
[Ti] Título:Hepatitis a virus genotypes and strains from an endemic area of Europe, Bulgaria 2012-2014.
[So] Source:BMC Infect Dis;17(1):497, 2017 Jul 14.
[Is] ISSN:1471-2334
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Hepatitis A virus (HAV) infection is endemic in Eastern European and Balkan region countries. In 2012, Bulgaria showed the highest rate (67.13 cases per 100,000) in Europe. Nevertheless, HAV genotypes and strains circulating in this country have never been described. The present study reports the molecular characterization of HAV from 105 patients from Bulgaria. METHODS: Anti-HAV IgM positive serum samples collected in 2012-2014 from different towns and villages in Bulgaria were analysed by nested RT-PCR, sequencing of the VP1/2A region and phylogenetic analysis; the results were analysed together with patient and geographical data. RESULTS: Phylogenetic analysis revealed two main sequence groups corresponding to the IA (78/105, 74%) and IB (27/105, 26%) sub-genotypes. In the IA group, a major and a minor cluster were observed (62 and 16 sequences, respectively). Most sequences from the major cluster (44/62, 71%) belonged to either of two strains, termed "strain 1" and "strain 2", differing only for a single specific nucleotide; the remaining sequences (18/62, 29%) showed few (1 to 4) nucleotide variations respect to strain 1 and 2. Strain 2 is identical to the strain previously responsible for an outbreak in the Czech Republic in 2008 and a large multi-country European outbreak caused by contaminated mixed frozen berries in 2013. Most sequences of the IA minor cluster and the IB group were detected in large/medium centers (LMCs). Overall, sequences from the IA major cluster were more frequent in small centers (SCs), but strain 1 and strain 2 showed an opposite relative frequency in SCs and LMCs (strain 1 more frequent in SCs, strain 2 in LMCs). CONCLUSIONS: Genotype IA predominated in Bulgaria in 2012-2014 and phylogenetic analysis identified a major cluster of highly related or identical IA sequences, representing 59% of the analysed cases; these isolates were mostly detected in SCs, in which HAV shows higher endemicity than in LMCs. The distribution of viral sequences suggests the existence of some differences between the transmission routes in SCs and LMCs. Molecular characterization of an increased number of isolates from Bulgaria, regularly collected over time, will be useful to explore specific transmission routes and plan appropriate preventing measures.
[Mh] Termos MeSH primário: Vírus da Hepatite A/genética
Hepatite A/virologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Bulgária/epidemiologia
Criança
Pré-Escolar
República Tcheca/epidemiologia
Surtos de Doenças
Feminino
Genótipo
Hepatite A/epidemiologia
Anticorpos Anti-Hepatite A/sangue
Vírus da Hepatite A/isolamento & purificação
Seres Humanos
Lactente
Recém-Nascido
Masculino
Filogenia
Reação em Cadeia da Polimerase
População Urbana
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hepatitis A Antibodies)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170715
[St] Status:MEDLINE
[do] DOI:10.1186/s12879-017-2596-1


  5 / 1151 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28651399
[Au] Autor:Liao Z; Feng XW; Liu XE; Zhou YS; Wen HR; Peng SH; Zhang YX; Xu B; Zhuang H; Chen HY
[Ad] Endereço:Nanchang Municipal Center for Disease Control and Prevention, Nanchang 330038, China.
[Ti] Título:[Immune response to one booster dose of inactivated hepatitis A vaccine in college students].
[So] Source:Zhonghua Liu Xing Bing Xue Za Zhi;38(5):625-628, 2017 May 10.
[Is] ISSN:0254-6450
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To evaluate the safety and immunogenicity of one booster dose of inactivated hepatitis A vaccine in young adults. The subjects were selected from participants in the clinical trial of immunogenicity of inactivated and attenuated live hepatitis A vaccine in young adults. Eligible subjects were those who had received one dose of inactivated or attenuated hepatitis A vaccine, could be contacted and were sero-negative before primary vaccination. All qualified subjects were immunized with one booster dose of inactivated hepatitis A vaccine. The blood samples were collected before booster dose vaccination and 28 days after the immunization. Anti-HAV antibody titer ≥20 mIU/ml was considered to be sero-protected against hepatitis A virus. The GMCs in the inactivated HAV vaccine group and attenuated live vaccine group before booster dose vaccination were 70.80 mIU/ml and 50.12 mIU/ml, respectively, and the sero-protection rates were 94.7 and 65.0 , respectively. After the vaccination of the booster dose, the sero-protection rates in both groups were 100.0 , and the GMCs were 2 816.09 mIU/ml and 2 654.55 mIU/ml, respectively. The GMCs and sero-protection rates of anti-HAV antibody in young adults declined after three years of the primary vaccination. However, the higher GMC and sero-protection rate were observed in the inactivated vaccine group than in the attenuated live vaccine group. Significant increases of GMC levels were observed in both groups after one booster dose vaccination.
[Mh] Termos MeSH primário: Anticorpos Anti-Hepatite A/sangue
Vacinas contra Hepatite A/imunologia
Vacinas contra Hepatite A/uso terapêutico
Hepatite A/prevenção & controle
Vacinação
Vacinas Atenuadas/administração & dosagem
Vacinas de Produtos Inativados/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Relação Dose-Resposta Imunológica
Feminino
Hepatite A/imunologia
Vacinas contra Hepatite A/efeitos adversos
Seres Humanos
Imunização Secundária
Masculino
Segurança
Estudantes
Vacinas Atenuadas/imunologia
Vacinas de Produtos Inativados/imunologia
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hepatitis A Antibodies); 0 (Hepatitis A Vaccines); 0 (Vaccines, Attenuated); 0 (Vaccines, Inactivated)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170904
[Lr] Data última revisão:
170904
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170628
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0254-6450.2017.05.013


  6 / 1151 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28592089
[Au] Autor:Kong Q; Yan BY; Lyu JJ; Feng Y; Liu JY; Song LZ; Xu Q; Zhang L; Xu AQ
[Ad] Endereço:School of Public Health, Shandong University, Jinan 250012, China.
[Ti] Título:[Prevalence of hepatitis A antibody among population covered by different hepatitis A immunization strategies in Shandong Province, 2015, China].
[So] Source:Zhonghua Yu Fang Yi Xue Za Zhi;51(6):480-483, 2017 Jun 06.
[Is] ISSN:0253-9624
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To evaluate prevalence of hepatitis A antibody (anti-HAV IgG) among population covered by different hepatitis A vaccine immunization strategies in Shandong Province in 2015. In October 2015, according to the geographical location of Shandong Province, the stratified random sampling method was used to stratify the 17 municipal distrcts, and the random number table method was used for sampling, First, two eastern cites (Qingdao, Rizhao), two western cities (Liaocheng, Zaozhuang) and three central cities (Jinan, Zibo and Laiwu) were selected; secondly, one county was drawn from each city. Finally, the participants were divided into five age groups including ≤7 years (age group covered by free hepatitis A vaccination strategy), 8-11 years (age group who receive hepatitis A vaccination at their own charge), 12-24 years (age group covered by catch-up vaccination of hepatitis A), 25-34 years (age group born before hepatitis A vaccine was used) and ≥35 years (age group born before hepatitis A vaccine was used). After all the paticipants or their guardians asked and registered basic information such as age, gender, home address, blood samples were collected from them and anti-HAV IgG was detected by ELISA method. The positive rate of anti-HAV IgG and 95% were calculated. A total of 1 654 participants were involved in the final analysis, including 856 males (51.75%) and 798 females (48.25%) whose mean age was (13.44±13.06) years. The crude positive rate of anti-HAV IgG was 91.41% (1 512/1 654, 95% 89.96%-92.72%) and the age-adjusted rate was 90.93% (95% 90.92%-90.94%). The positive rates of anti-HAV IgG was at the highest level in the age group of ≤7 years (95.90%, 95% 95.88%-95.91%) and was at the lowest level in the age group of 25-34 years (83.23%, 95% 83.21%-83.25%). The age-specific positive rates of anti-HAV IgG in eastern areas (96.79%, 95% 96.78%-96.80%) were higher than those in both middle areas (86.66%, 95% 86.65%-86.67%) and western areas (91.96%, 95% 91.95%-91.97%). The positive rate of anti-HAV IgG was high among the general population in Shandong Province, but relatively low among young and middle-aged adults. Besides the routine immunization of hepatitis A among the children, more efforts should be taken for the prevention and control of hepatitis A among young and middle-aged adults in Shandong Province, especially in central and western areas.
[Mh] Termos MeSH primário: Anticorpos Anti-Hepatite A/sangue
Vacinas contra Hepatite A/administração & dosagem
Hepatite A/epidemiologia
Imunização
Vigilância da População
[Mh] Termos MeSH secundário: Adolescente
Adulto
Criança
Pré-Escolar
China/epidemiologia
Ensaio de Imunoadsorção Enzimática
Feminino
Hepatite A/sangue
Vacinas contra Hepatite A/imunologia
Seres Humanos
Lactente
Masculino
Meia-Idade
Prevalência
Saccharomyces cerevisiae
Vacinação
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hepatitis A Antibodies); 0 (Hepatitis A Vaccines)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170609
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0253-9624.2017.06.005


  7 / 1151 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28498301
[Au] Autor:Bassal R; Weil M; Cohen D; Sofer D; Mendelson E; Shohat T
[Ad] Endereço:From the *Israel Center for Disease Control, Ministry of Health, Ramat-Gan, Israel; †Central Virology Laboratory, Chaim Sheba Medical Center, Tel Hashomer, Israel; and ‡Sackler Faculty of Medicine, School of Public Health, Tel Aviv University, Tel Aviv, Israel.
[Ti] Título:Seroprevalence of Hepatitis A Twelve Years After the Implementation of Toddlers' Vaccination: A Population-Based Study in Israel.
[So] Source:Pediatr Infect Dis J;36(10):e248-e251, 2017 Oct.
[Is] ISSN:1532-0987
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In 1999, Israel became the first country to introduce an inactivated hepatitis A vaccine into its national childhood vaccination program. The objective of the present study was to evaluate the seroprevalence of hepatitis A virus antibodies in the Israeli population before and after the introduction of the program. METHODS: A cross-sectional serosurvey using the National Serum Bank was conducted on 1883 and 2027 serum samples collected before and after introduction of the vaccine, respectively. Serologic tests for the presence of hepatitis A IgG antibodies were performed using an automated enzyme-linked fluorescent assay. RESULTS: The age-adjusted seroprevalence rates of hepatitis A virus antibodies before implementation of hepatitis A vaccination program were 47.1% [95% confidence interval (CI): 44.7%-49.5%] among Jews and 82.8% (95% CI: 79.6%-85.9%) among Arabs, increasing 12 years after to 67.4% (95% CI: 64.7%-70.0%) and 88.2% (95% CI: 86.1%-90.2%), respectively. CONCLUSIONS: The seropositivity rate among Jews and Arabs increased significantly among the cohorts included in the program. However, among Jews, a significant increase in seropositivity was also detected among age groups not included in the vaccination program. The decrease in the incidence of hepatitis A in Israel is a consequence of high vaccine uptake, persistent seropositivity rates after vaccination and the considerable number of people vaccinated beyond the program.
[Mh] Termos MeSH primário: Vacinas contra Hepatite A
Hepatite A/epidemiologia
Hepatite A/prevenção & controle
Vacinação/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Árabes/estatística & dados numéricos
Criança
Pré-Escolar
Estudos Transversais
Anticorpos Anti-Hepatite A/sangue
Vacinas contra Hepatite A/administração & dosagem
Vacinas contra Hepatite A/imunologia
Seres Humanos
Lactente
Recém-Nascido
Israel/epidemiologia
Judeus/estatística & dados numéricos
Meia-Idade
Estudos Soroepidemiológicos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hepatitis A Antibodies); 0 (Hepatitis A Vaccines)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170929
[Lr] Data última revisão:
170929
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170513
[St] Status:MEDLINE
[do] DOI:10.1097/INF.0000000000001640


  8 / 1151 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28426700
[Au] Autor:Neffatti H; Lebraud P; Hottelet C; Gharbi J; Challouf T; Roque-Afonso AM
[Ad] Endereço:AP-HP, Hôpital Paul Brousse, Virologie, Villejuif, France.
[Ti] Título:Southern Tunisia: A still high endemicity area for hepatitis A.
[So] Source:PLoS One;12(4):e0175887, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Hepatitis A (HAV) and E (HEV) viruses are responsible for enterically transmitted hepatitis. Tunisia is reported to be of intermediate endemicity for HAV and of low seroprevalence for HEV; however, data from rural areas of South Tunisia are lacking. METHODS: Sera from 216 asymptomatic pregnant women and from 92 patients with acute hepatitis were collected between October 2014 and November 2015. Total and IgM anti-HAV immunoglobulins and anti-HEV IgG and IgM were investigated. Anti-HAV IgM-positive samples were subjected to RT-PCR targeting the VP1/2A region and sequenced. HEV IgM positive samples and all samples from acute hepatitis patients were assessed for HEV RNA. RESULTS: Among pregnant women (mean age 32+/-8), HAV seroprevalence was 98.6%, none presented anti-HAV IgM; HEV seroprevalence was 5.1% and three presented weakly reactive anti-HEV IgM without detectable RNA. Among acute hepatitis patients (mean age 18.5 +/- 14), HEV seroprevalence was 19,5%, none presented anti-HEV IgM, nor HEV RNA. HAV seroprevalence exceeded 90% by age 5 and acute HAV infection was detected in 20 patients (21,7%), younger than patients with other hepatitis causes (9,8 years vs. 20,4 years, p = 0,004); 65% were male. Most acute HAV infections were observed in a coastal area where HAV infections represented 52% of hepatitis etiology. Phylogenetic analysis identified genotype IA strains, clustering close to previously published Tunisian sequences. CONCLUSION: The present study confirmed a low HEV endemicity and evidenced a still high level of HAV circulation in Southern Tunisia, suggesting distinct dissemination patterns for these viruses.
[Mh] Termos MeSH primário: Hepatite A/epidemiologia
[Mh] Termos MeSH secundário: Adulto
Doenças Endêmicas
Feminino
Anticorpos Anti-Hepatite A/sangue
Vírus da Hepatite A/genética
Vírus da Hepatite A/imunologia
Vírus da Hepatite E/genética
Vírus da Hepatite E/imunologia
Seres Humanos
Imunoglobulina M/sangue
Masculino
Filogenia
Gravidez
Complicações Infecciosas na Gravidez/epidemiologia
RNA Viral/sangue
Tunísia/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hepatitis A Antibodies); 0 (Immunoglobulin M); 0 (RNA, Viral)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170421
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0175887


  9 / 1151 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28281464
[Au] Autor:Maritsi DN; Eleftheriou D; Onoufriou M; Vartzelis G
[Ad] Endereço:Second Department of Paediatrics, "P. & A. Kyriakou" Children's Hospital, University of Athens, Greece; and Makarios III Children's' Hospital, Nicosia, Cyprus. dmaritsi@gmail.com.
[Ti] Título:Decreased antibodies against hepatitis A in previously vaccinated treatment naïve juvenile SLE patients: a prospective case control study.
[So] Source:Clin Exp Rheumatol;35(3):544-545, 2017 May-Jun.
[Is] ISSN:0392-856X
[Cp] País de publicação:Italy
[La] Idioma:eng
[Mh] Termos MeSH primário: Anticorpos Anti-Hepatite A/sangue
Vacinas contra Hepatite A/administração & dosagem
Vírus da Hepatite A/imunologia
Hepatite A/prevenção & controle
Lúpus Eritematoso Sistêmico/imunologia
[Mh] Termos MeSH secundário: Adolescente
Idade de Início
Biomarcadores/sangue
Estudos de Casos e Controles
Criança
Feminino
Hepatite A/sangue
Hepatite A/diagnóstico
Hepatite A/imunologia
Seres Humanos
Imunogenicidade da Vacina
Lúpus Eritematoso Sistêmico/sangue
Lúpus Eritematoso Sistêmico/diagnóstico
Masculino
Estudos Prospectivos
[Pt] Tipo de publicação:LETTER
[Nm] Nome de substância:
0 (Biomarkers); 0 (Hepatitis A Antibodies); 0 (Hepatitis A Vaccines)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170924
[Lr] Data última revisão:
170924
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170311
[St] Status:MEDLINE


  10 / 1151 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28099530
[Au] Autor:Kim KA; Lee A; Ki M; Jeong SH
[Ad] Endereço:Departments of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Republic of Korea.
[Ti] Título:Nationwide Seropositivity of Hepatitis A in Republic of Korea from 2005 to 2014, before and after the Outbreak Peak in 2009.
[So] Source:PLoS One;12(1):e0170432, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIMS: The epidemiologic shift of hepatitis A virus (HAV) infection in the South Korean population resulted in a peak outbreak of hepatitis in 2009. The aim of this study was to clarify the seropositivity of anti-HAV antibody (anti-HAV) and its demographic characteristics before and after the peak outbreak from 2005 to 2014. METHODS: This retrospective study analyzed the anti-HAV data of all individuals from 1,795 medical institutions referred to a major central laboratory from January 2005 through December 2014, as a sentineal tool for monitoring annual variation of anti-HAV positivity. The prevalence of anti-HAV was adjusted for age and area with the standard population based on the 2010 Census data. RESULTS: A total of 424,245 individuals were included in this study. The overall age-adjusted anti-HAV prevalence decreased from 65.6% in 2005 to 62.2% in 2014. During the 10-year period, the seroprevalence continuously decreased in persons aged 30 to 39 years (69.6% to 32.4%) and those aged 40 to 49 years (97.9% to 79.3%) due to the cohort effect. In contrast, it increased in persons aged 10 to 19 years (15.4% to 35.2%), while it was the lowest (8.7%) in 2010 before rebounding to 20.2% in 2014 in persons aged 20 to 29 years due to a vaccination effect. CONCLUSION: Although the HAV vaccination rate increased, the anti-HAV seropositivity in South Korea decreased from 65.6% to 62.2% in this study population. In particular, the immunity of young adults was still low, and an outbreak of HAV is possible in the near future. Therefore, continuous monitoring and optimal preventive measures to prevent future outbreaks should be considered.
[Mh] Termos MeSH primário: Anticorpos Anti-Hepatite A/sangue
Vírus da Hepatite A/imunologia
Hepatite A/epidemiologia
Estudos Soroepidemiológicos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Criança
Pré-Escolar
Surtos de Doenças
Feminino
Seres Humanos
Lactente
Recém-Nascido
Masculino
Meia-Idade
República da Coreia/epidemiologia
Estudos Retrospectivos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hepatitis A Antibodies)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170816
[Lr] Data última revisão:
170816
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170119
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0170432



página 1 de 116 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde